Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status

JAMA Oncology

Volumn 1, Issue 8, 2015, Pages 1069-1077

  Miglioretti, Diana L ^a,b   Zhu, Weiwei ^b   Kerlikowske, Karla ^c   Sprague, Brian L ^d,e   Onega, Tracy ^f   Buist, Diana S M ^b   Henderson, Louise M ^g   Smith, Robert A ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE EFFECTS; AGE; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MIDDLE AGED; ODDS RATIO; PATHOLOGY; POSTMENOPAUSE; PREDICTIVE VALUE; PREMENOPAUSE; PROCEDURES; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR BURDEN;

EID: 85010903347     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3084     Document Type: Article

References (43)

1. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-726, W-236.
2. Mandelblatt JS, Cronin KA, Bailey S, et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.
3. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88-105.
4. American College of Obstetricians-Gynecologists. Practice Bulletin No. 122: breast cancer screening. Obstet Gynecol. 2011;118(2, pt 1):372-382.
5. Bevers TB, Anderson BO, Bonaccio E, et al; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
6. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18-27.
7. Ichikawa LE, Barlow WE, Anderson ML, Taplin SH, Geller BM, Brenner RJ; National Cancer Institute-sponsored Breast Cancer Surveillance Consortium. Time trends in radiologists' interpretive performance at screening mammography from the community-based Breast Cancer Surveillance Consortium, 1996-2004. Radiology. 2010;256(1):74-82.
8. Kerlikowske K, Hubbard RA, Miglioretti DL, et al; Breast Cancer Surveillance Consortium. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155(8):493-502.
9. Brawley OW. Risk-based mammography screening: an effort to maximize the benefits and minimize the harms. Ann Intern Med. 2012;156(9): 662-663.
10. Vilaprinyo E, Forné C, Carles M, et al; Interval Cancer (INCA) Study Group. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9(2): e86858.
11. Mandelblatt JS, Stout N, Trentham-Dietz A. To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer? Ann Intern Med. 2011;155(1):58-60.
12. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer. 2014;120(19):2955-2964.
13. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155(1):10-20.
14. Tabár L, Faberberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? an analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer. 1987;55(5):547-551.
15. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer. 1996;66(4):413-419.
16. Baker LH. Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin. 1982;32(4):194-225.
17. Tabár L, Fagerberg CJ, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1(8433):829-832.
18. Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst. 2004; 96(19):1432-1440.
19. Anderson TJ, Waller M, Ellis IO, Bobrow L, Moss S. Influence of annual mammography from age 40 on breast cancer pathology. Hum Pathol. 2004;35 (10):1252-1259.
20. White E, Miglioretti DL, Yankaskas BC, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst. 2004;96(24):1832-1839.
21. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481-492.
22. Kerlikowske K, Zhu W, Hubbard RA, et al; Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173(9):807-816.
23. Dittus K, Geller B, Weaver DL, et al; Breast Cancer Surveillance Consortium. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013;28(11):1454-1462.
24. Braithwaite D, Zhu W, Hubbard RA, et al; Breast Cancer Surveillance Consortium. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst. 2013;105(5):334-341.
25. O'Meara ES, Zhu W, Hubbard RA, et al. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer. 2013;119(22):3959-3967.
26. Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007;120(5): 1076-1080.
27. Randall D, Morrell S, Taylor R, Hung WT. Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia. Cancer Causes Control. 2009;20(5):559-566.
28. Goel A, Littenberg B, Burack RC. The association between the pre-diagnosis mammography screening interval and advanced breast cancer. Breast Cancer Res Treat. 2007;102 (3):339-345.
29. van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156(9):609-617.
30. Stout NK, Lee SJ, Schechter CB, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106(6):dju092.
31. O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med. 2014;160(3):145-153.
32. Ballard-Barbash R, Taplin SH, Yankaskas BC, et al; Breast Cancer Surveillance Consortium. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol. 1997;169(4):1001-1008.
33. Sickles EA, Miglioretti DL, Ballard-Barbash R, et al. Performance benchmarks for diagnostic mammography. Radiology. 2005;235(3):775-790.
34. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546-1554.
35. Breast Cancer Surveillance Consortium. BCSC Glossary of Terms. 2009. http://breastscreening.cancer.gov/data/bcsc-data-definitions.pdf. Accessed March 9, 2015.
36. Phipps AI, Ichikawa L, Bowles EJ, et al. Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas. 2010;67 (1):60-66.
37. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23): 4314-4321.
38. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
39. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157 (10):940-943.
40. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138(3):168-175.
41. Kerlikowske K, Ichikawa L, Miglioretti DL, et al; National Institutes of Health Breast Cancer Surveillance Consortium. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007;99(5):386-395.
42. Pisano ED, Gatsonis C, Hendrick E, et al; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773-1783.
43. Pisano ED, Hendrick RE, Yaffe MJ, et al; DMIST Investigators Group. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology. 2008;246(2):376-383.